GLP-1s and Cancer: Promising New Research Suggests Their Benefits May Extend Beyond Weight Loss

Medically reviewed by Dr. Mario Menendez, MD | Medical Director, Lowcountry Male

GLP-1 medications have transformed the conversation around medical weight loss, obesity, diabetes, and metabolic health. Now, new research is raising an entirely different and intriguing question: Could GLP-1 medications also influence how certain cancers progress?

It’s a question worth digging into. A large study examined patients with seven different types of cancer who began taking a GLP-1 medication after their cancer diagnosis. It was published in the Journal of Clinical Oncology and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

The researchers found that these patients were much less likely to see their cancer spread to stage IV disease. That was especially true for those with breast, lung, colorectal, and liver cancer.

The findings are promising. But they need careful interpretation.

This study looked back at existing patient health records rather than following patients forward in a controlled experiment. That means the research identified a pattern between taking a GLP-1 medication and lower rates of cancer spreading. It does not prove that GLP-1 medications prevented cancer from spreading. And it does not establish GLP-1 medications as cancer treatments.

Still, the findings create an interesting scientific signal. They raise new questions about how GLP-1 medications, metabolic health, inflammation, and immunity might connect to cancer biology.

Key Takeaways

• 10,225 patients identified: Researchers identified more than 10,000 people with early-stage cancer who began taking a GLP-1 medication after their diagnosis.
• Four significant patterns: GLP-1 use was linked to significantly less cancer spreading in breast, lung, colorectal, and liver cancer.
• Promising, not proof: This type of study can reveal a strong pattern. But it can’t prove that the medication caused the results. Larger, forward-looking clinical trials are needed to confirm.

What Did the 2026 GLP-1 Cancer Study Examine?

A team affiliated with Cleveland Clinic led the research. They presented their findings at the 2026 ASCO Annual Meeting, one of the world’s largest cancer research conferences.

Researchers used a large database of real-world patient health records. They identified 10,225 patients with stage I, II, or III cancer who started a GLP-1 medication after their diagnosis. The study included seven types of cancer:

1. Breast cancer
2. Non-small cell lung cancer, the most common type of lung cancer
3. Colorectal cancer
4. Liver cancer (hepatocellular carcinoma)
5. Prostate cancer
6. Kidney cancer (renal cell carcinoma)
7. Pancreatic cancer

Researchers compared these patients to a similar group taking a different diabetes medication called a DPP-4 inhibitor.

To make the two groups as alike as possible, researchers carefully matched patients on factors that could affect cancer outcomes. That included age, weight, smoking history, blood sugar-related factors, other health conditions, how often patients were screened for cancer, and the treatments they received.

After this matching, the final analysis included 6,056 patients in the GLP-1 group and 6,056 in the DPP-4 group. Researchers then tracked how many patients in each group saw their cancer progress to stage IV, or metastatic, disease.

What Did the Study Find?

Patients taking GLP-1 medications had lower rates of cancer spreading in six of the seven cancers studied. In four of those cancers, breast, lung, colorectal, and liver, the difference was large enough that researchers are confident it wasn’t simply due to chance.

Breast Cancer

The breast cancer findings may be particularly meaningful for women.

Among patients with breast cancer, 10.2% of those taking a GLP-1 medication saw their cancer spread. That compares with 20.1% of patients taking a DPP-4 inhibitor. Patients on a GLP-1 medication were roughly half as likely to see their breast cancer progress to stage IV.

That doesn’t mean any individual woman’s personal risk is cut in half. It describes a pattern seen across a large group of patients, not a guarantee for any one person.

Non-Small Cell Lung Cancer

Among patients with lung cancer, 10.0% of GLP-1 users saw their cancer spread. That compares with 22.3% of patients taking a DPP-4 inhibitor.

Colorectal Cancer

Among patients with colorectal cancer, 13.4% of GLP-1 users saw their cancer spread. That compares with 22.2% of the comparison group.

Liver Cancer

Among patients with liver cancer, 18.9% of GLP-1 users saw their cancer spread. That compares with 28.4% of patients taking a DPP-4 inhibitor.

Researchers also saw numerically lower rates of cancer spreading in patients with prostate, pancreatic, and kidney cancer. But those differences were small enough that they could have happened by chance. That distinction matters. It means the study didn’t provide strong enough evidence to say those particular results reflect a real effect.

Why This Study Is Promising, But Not Proof

The numbers understandably attract attention. But the study type matters as much as the numbers themselves.

This research looked backward at existing, real-world patient data. It aimed to find links between medication use and cancer outcomes. Careful matching strengthens this kind of analysis. But even the most thoughtful matching can’t account for every possible difference between two patient groups. Differences in lifestyle, healthcare access, or how closely patients followed treatment may exist. Not all of these could be fully captured.

That is why a study like this can identify a strong signal without proving what caused it.

As Aqua Vitae’s Medical Director Mario Menendez, MD, explains:

“While this research does not establish that GLP-1 medications treat or prevent cancer, and it’s important that we don’t make that leap, the findings of this large study group are promising. This was a well-designed retrospective observational study, not a prospective randomized controlled trial. But the signal is compelling.

When we see this kind of consistency across several tumor types, it raises an important biological question: Is there a reasonable hypothesis that GLP-1 signaling, metabolic health, inflammation, and immune function may intersect with cancer biology and mitigate risks? The next step is prospective research designed to determine whether that relationship is causal and, if so, why.”

Mario Menendez, MD, Medical Director, Aqua Vitae

In other words, this isn’t the end of the scientific conversation; it’s just the beginning. It’s a good reason to keep studying the connection between GLP-1 medications and cancer.

Why Might GLP-1 Medications Be Connected to Cancer Progression?

Here’s where it gets really interesting.

GLP-1 medications were originally developed to help manage type 2 diabetes. Today, they’re also widely used to treat obesity and support weight management. Their effects extend well beyond appetite and the number on the scale.

GLP-1 medications can affect blood sugar, insulin levels, body weight, and heart health. Researchers are also interested in how they might affect inflammation and immune function. Those pathways matter because cancer doesn’t exist on its own; it’s connected to the body’s overall biology. Obesity, insulin resistance, metabolic dysfunction, chronic inflammation, and immune signaling are all active areas of cancer research.

That raises several intriguing questions.

• Could improving metabolic health create a biological environment that’s less favorable to cancer growth?
• Could changes in inflammation play a role?
• Could immune function be involved?
• Could GLP-1 medications have a more direct relationship with tumor cells?
• Or could several of these mechanisms be working together?

At this point, these are possible explanations, not established conclusions. But the new research gives scientists another reason to investigate them.

Another Interesting Finding: GLP-1 Receptors Within Tumors

Researchers also explored a related question. They used genetic data from tumor samples to see whether the amount of GLP-1 receptor activity within a tumor was linked to patient survival.

Across the seven tumor types studied, tumors with higher GLP-1 receptor activity were linked to a 33% lower risk of death compared with tumors with lower receptor activity. This link was especially notable in breast cancer, where higher GLP-1 receptor activity was linked to a 45% lower risk of death.

This finding also needs to be read cautiously. The amount of GLP-1 receptor activity in a tumor and a patient actually taking a GLP-1 medication are two different biological questions. This part of the analysis doesn’t establish that taking a GLP-1 medication improves survival.

Still, it adds another piece of scientific rationale for studying this connection more closely.

What Does This Mean for Women Taking GLP-1 Medications?

If you’re taking a GLP-1 medication, or thinking about it, here’s the honest answer: for now, these findings shouldn’t change how cancer is treated.

Based on this study, GLP-1 medications should not be considered cancer treatments. No one should begin a GLP-1 medication specifically to try to prevent their cancer from spreading. Likewise, patients shouldn’t stop or change a prescribed medication because of these findings without first talking to their doctor.

For women who currently have cancer or are undergoing cancer treatment, decisions about GLP-1 therapy should always involve their oncologist and care team.

This research reinforces how interconnected our health really is.

Metabolic Health Is About More Than Weight

When most people hear “GLP-1,” they immediately think about weight loss. But metabolic health involves much more than body weight. It includes blood sugar regulation, insulin sensitivity, body composition, heart health, inflammation, hormones, nutrition, sleep, and physical activity. These systems don’t operate in isolation.

That’s one reason research connecting metabolic health, obesity, inflammation, immune function, and disease matters so much. This emerging research gives scientists another opportunity to understand how those pieces fit together.

What Happens Next?

The next major step is more research, including forward-looking clinical trials that follow patients over time rather than looking back at existing records. That kind of study makes it easier for researchers to determine whether a treatment itself is actually causing a difference in outcomes, rather than simply being linked to it.

If future studies find the same patterns, the next question becomes even more interesting: why?

Is improved metabolic health responsible? Is weight loss a major factor? Does better insulin sensitivity matter? Is inflammation involved? Does the immune system play a role? Could GLP-1 medications affect cancer cells directly?

The current study can’t answer those questions. But it gives researchers a compelling reason to ask them.

That’s how medical science tends to advance. A pattern shows up in real-world data. Scientists come up with ideas. Controlled studies test those ideas. Findings are confirmed and refined before treatment recommendations ever change.

Promising Research Worth Watching

It would be easy to sum up this study with a dramatic headline claiming that GLP-1 medications stop cancer from spreading. That isn’t what the research shows.

A more accurate conclusion is also a more interesting one. In this large real-world study, patients who started a GLP-1 medication after an early-stage breast, lung, colorectal, or liver cancer diagnosis were much less likely to see their cancer spread. That was compared with patients taking a different diabetes medication.

That pattern is promising and worth paying attention to. But it isn’t proof of cause and effect. We don’t yet know whether GLP-1 medications themselves made the difference, whether the findings reflect improvements in metabolic health, or whether several factors are working together.

Future research may help answer those questions. For now, there’s a signal worth watching closely, and we’ll keep an eye on where the science leads.

Frequently Asked Questions About GLP-1s and Cancer

Do GLP-1 medications prevent cancer?

There isn’t enough evidence to say that GLP-1 medications prevent cancer. This study only included patients who already had early-stage cancer. So it looked at whether the medication was linked to less cancer spreading. It did not look at whether GLP-1 medications prevent cancer from developing in the first place.

Can GLP-1 medications stop cancer from spreading?

GLP-1 medications aren’t an established treatment for stopping cancer from spreading. This study found lower rates of cancer spreading among GLP-1 users with breast, lung, colorectal, and liver cancer. This was compared with patients taking a different diabetes medication. Forward-looking clinical trials are needed to determine whether the medication itself contributed to that difference.

What did the 2026 GLP-1 cancer study find?

Researchers identified 10,225 patients with early-stage cancer who began a GLP-1 medication after their diagnosis. After careful matching, they compared 6,056 GLP-1 users with 6,056 patients taking a different diabetes medication. GLP-1 use was linked to significantly lower rates of cancer spreading in breast, lung, colorectal, and liver cancer.

What did the study find about GLP-1s and breast cancer?

Among patients with breast cancer, 10.2% of GLP-1 users saw their cancer spread, compared with 20.1% of patients on the comparison medication. This is a meaningful pattern, but it doesn’t prove that GLP-1 medications prevented the cancer from spreading.

Which cancers were included in the study?

Researchers studied seven types: breast, lung, colorectal, liver, prostate, kidney, and pancreatic cancer. Statistically significant patterns were found in breast, lung, colorectal, and liver cancer.

Why might GLP-1 medications be related to cancer progression?

Researchers don’t yet know. Possible explanations include improved metabolic health, changes in insulin signaling, reduced inflammation, immune activity, and effects on tumor biology. These are hypotheses that need more research, not established mechanisms.

Are GLP-1 medications cancer treatments?

No. Based on this research, GLP-1 medications should not be considered cancer treatments. These findings are observational and require confirmation through further clinical research.

Should someone with cancer take a GLP-1 medication?

A patient should make that decision with their own doctors, including their oncology team. This research isn’t enough evidence to recommend starting a GLP-1 medication just to treat cancer or stop it from spreading.

Sources & Further Reading

• Orland MD, Mandala A, Unlu S, et al. Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors. Journal of Clinical Oncology. 2026;44(16_suppl):3143. doi:10.1200/JCO.2026.44.16_suppl.3143. Presented at the 2026 American Society of Clinical Oncology Annual Meeting.
• American Society of Clinical Oncology (ASCO). GLP-1s May Reduce Metastatic Progression of Certain Obesity-Related Cancers.

Medical Disclaimer

This article is provided for educational and informational purposes only and should not be considered medical advice. The research discussed is observational and does not establish that GLP-1 receptor agonists prevent, treat, cure, or reduce cancer progression. Based on this research, GLP-1 receptor agonists are not established cancer treatments. Patients with a current or previous cancer diagnosis should discuss medication and treatment decisions with their oncologist and healthcare team.